ReviewAdvanced drug delivery reviews2012
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.
Review in Advanced drug delivery reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Probiotic Carriers for Tumor-Targeted Therapy: Applications and Challenges.International journal of nanomedicine · 2026Review
- Modified probiotics and the related combinatorial therapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Indocyanine Green-Loaded Quenched Nanoliposomes as Activatable Theranostics for Cancer.Molecules (Basel, Switzerland) · 2025Article
- Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.BioImpacts : BI · 2025Review
- Nucleic acid-based drugs for patients with solid tumours.Nature reviews. Clinical oncology · 2024Review
- Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery.Drug delivery and translational research · 2024Article
- Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomes Co-Loaded with Cisplatin and Mifepristone.Pharmaceuticals (Basel, Switzerland) · 2023Article
- IntracellularFrontiers in immunology · 2023Article
- In Vitro and In Vivo Effect of pH-Sensitive PLGA-TPGS-Based Hybrid Nanoparticles Loaded with Doxorubicin for Breast Cancer Therapy.Pharmaceutics · 2022Article
- mRNA nanomedicine: Design and recent applications.Exploration (Beijing, China) · 2022Review
- αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma.Journal of nanobiotechnology · 2022Article
- A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives.Molecules (Basel, Switzerland) · 2022Review
- A Stepwise Framework for the Systematic Development of Lipid Nanoparticles.Biomolecules · 2022Article
- Virus-Mimicking Cell Membrane-Coated Nanoparticles for Cytosolic Delivery of mRNA.Angewandte Chemie (International ed. in English) · 2022Article
- Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, andBioMed research international · 2022Article
- Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases.Nature communications · 2021Article
- Influencing factors and strategies of enhancing nanoparticles into tumorsActa pharmaceutica Sinica. B · 2021Review
- Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications.Cancers · 2021Review
- A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy.Pharmaceutics · 2021Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Advances in molecular medicines have led to identification of promising targets on cellular and molecular levels. These targets are located in extracellular and intracellular compartments. The latter include cytosol, nucleus, mitochondrion, Golgi apparatus and endoplasmic reticulum. This report gives an overview on the barriers to delivering nanomedicines to various target sites within a solid tumor, the experimental approaches to overcome such barriers, and the potential utility of nanotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.